Inventor · disambiguated record
Allen B. Reitz
Also filed as: REITZ ALLEN · REITZ ALLEN B
101 granted patents·48 pending applications·806 citations·filing 1985–2025
99Inventor score
Files withORTHO MCNEIL PHARM INC21BIOHAVEN THERAPEUTICS LTD14BIOHAVEN PHARM HOLDING CO LTD11JANSSEN PHARMACEUTICA NV10SMITH-SWINTOSKY VIRGINIA L9
Top patents by PatentIndex Score
149 records- 0197US11052070B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2019·Granted Jul 6, 2021·9 cites·3 claims
- 0297US10639298B2Prodrugs of riluzole and their method of useBIOHAVEN PHARM HOLDING CO LTD·Filed 2016·Granted May 5, 2020·12 cites·10 claims
- 0397US10485791B2Riluzole prodrugs and their useBIOHAVEN PHARM HOLDING CO LTD·Filed 2016·Granted Nov 26, 2019·18 cites·4 claims
- 0496US12005047B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2023·Granted Jun 11, 2024·2 cites·6 claims
- 0596US10905681B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2019·Granted Feb 2, 2021·15 cites·11 claims
- 0695US10357497B2Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosisBIOHAVEN PHARM HOLDING CO LTD·Filed 2013·Granted Jul 23, 2019·12 cites·4 claims
- 0795US9725427B2Prodrugs of riluzole and their method of useBIOHAVEN PHARM HOLDING CO LTD·Filed 2013·Granted Aug 8, 2017·20 cites·11 claims
- 0894US6291476B1Pyrazole carboxamides useful for the treatment of obesity and other disordersORTHO MCNEIL PHARM INC·Filed 2000·Granted Sep 18, 2001·47 cites·16 claims
- 0994US6140354AN-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disordersORTHO MCNEIL PHARM INC·Filed 1999·Granted Oct 31, 2000·152 cites·22 claims
- 1092US11440893B2Prodrugs of riluzole and their method of useBIOHAVEN PHARM HOLDING CO LTD·Filed 2020·Granted Sep 13, 2022·2 cites·5 claims
- 1192US11242317B2EBNA1 inhibitors and their method of useWISTAR INST·Filed 2019·Granted Feb 8, 2022·4 cites·17 claims
- 1292US6465486B1Pyridyl/quinolinyl imidazolesORTHO MCNEIL PHARM INC·Filed 2000·Granted Oct 15, 2002·38 cites·4 claims
- 1391US11911369B2Prodrugs of riluzole and their method of useBIOHAVEN THERAPEUTICS LTD·Filed 2020·Granted Feb 27, 2024·2 cites·9 claims
- 1491US10981867B2EBNA1 inhibitors and methods using sameWISTAR INST·Filed 2019·Granted Apr 20, 2021·3 cites·13 claims
- 1591US10442763B2EBNA1 inhibitors and methods using sameWISTAR INST·Filed 2016·Granted Oct 15, 2019·4 cites·5 claims
- 1690US11197864B2Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosisBIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD B·Filed 2019·Granted Dec 14, 2021·4 cites·8 claims
- 1790US10844026B2Prodrugs of riluzole and their method of useBIOHAVEN PHARM HOLDING CO LTD·Filed 2020·Granted Nov 24, 2020·2 cites·7 claims
- 1890US6511998B2Pyrazole carboxamides useful for the treatment of obesity and other disordersFiled 2001·Granted Jan 28, 2003·28 cites·16 claims
- 1989US12472165B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2023·Granted Nov 18, 2025·0 cites·4 claims
- 2089US8084490B2Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disordersMCCOMSEY DAVID F·Filed 2005·Granted Dec 27, 2011·10 cites·20 claims
- 2188US10562870B2Prodrugs of riluzole and their method of useBIOHAVEN PHARM HOLDING CO LTD·Filed 2017·Granted Feb 18, 2020·2 cites·3 claims
- 2288US7319107B21,2,4-thiadiazolium derivatives as melanocortin receptor modulatorsJOHNSON & JOHNSON CONSUMER·Filed 2002·Granted Jan 15, 2008·25 cites·25 claims
- 2388US6436959B14-[aryl(piperidin-4-yl)]aminobenzamidesORTHO MCNEIL PHARM INC·Filed 1998·Granted Aug 20, 2002·45 cites·8 claims
- 2487US7375123B21,2,4-thiadiazole derivatives as melanocortin receptor modulatorsORTHO MCNEIL PHARM INC·Filed 2006·Granted May 20, 2008·10 cites·9 claims
- 2587US7049331B21,2,4-thiadiazole derivatives as melanocortin receptor modulatorsORTHO MCNEIL PHARM INC·Filed 2002·Granted May 23, 2006·26 cites·19 claims
- 2686US7531545B22-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of β-secretase (BACE)JANSSEN PHARMACEUTICA NV·Filed 2006·Granted May 12, 2009·14 cites·14 claims
- 2785US7786311B21,2,4-thiadiazolium derivatives as melanocortin receptor modulatorsORTHO MCNEIL PHARM INC·Filed 2008·Granted Aug 31, 2010·6 cites·3 claims
- 2885US5569659A4-arylpiperazines and 4-arylpiperidinesMCNEILAB INC·Filed 1995·Granted Oct 29, 1996·35 cites·30 claims
- 2984US7582649B2Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disordersJANSSEN PHARMACEUTICA NV·Filed 2005·Granted Sep 1, 2009·7 cites·14 claims
- 3084US2024246909A1EBNA1 Inhibitors and Methods Using SameWISTAR INST·Filed 2024·Application pending·0 cites
- 3182US12172974B2Prodrugs of riluzole and their method of useBIOHAVEN PHARM HOLDING CO LTD·Filed 2022·Granted Dec 24, 2024·0 cites·8 claims
- 3281US11306075B2Benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of useOLIGOMERIX INC·Filed 2017·Granted Apr 19, 2022·2 cites·9 claims
- 3381US5332732AThiophene and pyridine antipsychotic agentsMCNEILAB INC·Filed 1992·Granted Jul 26, 1994·24 cites·22 claims
- 3480US7018797B2Method for treating neurodegenerative disordersORTHO MCNEIL PHARM INC·Filed 2002·Granted Mar 28, 2006·11 cites·8 claims
- 3579US12213965B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2021·Granted Feb 4, 2025·0 cites·5 claims
- 3679US7081463B2Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disordersJANSSEN PHARMACEUTICA NV·Filed 2003·Granted Jul 25, 2006·11 cites·15 claims
- 3778US12005046B2Riluzole prodrugs and their useBIOHAVEN THERAPEUTICS LTD·Filed 2021·Granted Jun 11, 2024·0 cites·8 claims
- 3878US7868022B22-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)JANSSEN PHARMACEUTICA NV·Filed 2007·Granted Jan 11, 2011·5 cites·15 claims
- 3978US6777421B21,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disordersORTHO MCNEIL PHARM INC·Filed 2002·Granted Aug 17, 2004·11 cites·14 claims
- 4078US6441049B2Method of treating neurodegenerative disorders via inhibition of amyloid beta peptide bindingORTHO MCNEIL PHARM INC·Filed 1999·Granted Aug 27, 2002·37 cites·14 claims
- 4177US12258314B2EBNA1 inhibitors and their method of useWISTAR INST·Filed 2021·Granted Mar 25, 2025·0 cites·7 claims
- 4276US12343347B2Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosisBIOHAVEN PHARM HOLDING CO LTD·Filed 2021·Granted Jul 1, 2025·0 cites·3 claims
- 4376US11472776B2Quinazolinones that inhibit the formation of tau oligomers and their method of useOLIGOMERIX INC·Filed 2017·Granted Oct 18, 2022·1 cites·8 claims
- 4476US10421718B2EBNA1 inhibitors and their method of useWISTAR INST·Filed 2017·Granted Sep 24, 2019·1 cites·24 claims
- 4576US2024358685A1Acyl benzo[d]thiazol-2-amine and their methods of useBIOHAVEN THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 4676US2025304565A1Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of useOLIGOMERIX INC·Filed 2025·Application pending·0 cites
- 4775US11912659B2EBNA1 inhibitors and methods using sameWISTAR INST·Filed 2021·Granted Feb 27, 2024·0 cites·10 claims
- 4874US8716231B2Use of benzo-fused heterocycle sulfamide derivatives for the treatment of painSMITH-SWINTOSKY VIRGINIA L·Filed 2006·Granted May 6, 2014·2 cites·9 claims
- 4974US7932261B2Macrocycle derivatives useful as inhibitors of β-secretase (BACE)JANSSEN PHARMACEUTICA NV·Filed 2007·Granted Apr 26, 2011·2 cites·8 claims
- 5074US7053101B21,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disordersJORDAN ALFONZO·Filed 2004·Granted May 30, 2006·12 cites·8 claims
Showing the top 50 of 149 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Allen B. Reitz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →